Teriparatide Plus Denosumab Together: Is Concurrent Therapy Worth the Uncertainty
A single patient severe enough that the usual sequential playbook feels too slow. The disagreement is whether combining two drug classes at once is justified by her numbers, or whether it's reaching past what the evidence actually supports.
Adelina C., a 74-year-old woman, has broken three separate bones in the past eighteen months — a wrist, a rib, and now a second vertebral compression fracture at T11 — each from a fall or strain that, by her own description, would not have troubled her a few years ago. She still lives alone in the house she raised her children in, and she raised the fear herself, before anyone on the team brought it up, of a fall that lands her somewhere she cannot get up from. She was started on alendronate after the first of those fractures and has taken it faithfully since, which is what makes the third one land differently than a first fracture would.
Her repeat DXA on that therapy shows a lumbar spine T-score that has risen from −3.1 to −2.7. The drug did what it is supposed to do to the number, and she broke three bones anyway. That mismatch is the whole difficulty: a patient whose density is falling on treatment has a legible problem, and the answer is to change agents. Adelina's density is improving on treatment, which means whatever is producing her fractures is not being captured by the measurement the group would ordinarily use to decide. Sequential anabolic-then-antiresorptive therapy is the conventional next step after a bisphosphonate is judged to have failed, and it does not feel proportionate to everyone in the room, because it asks her to spend a year finding out whether a sequence works. Concurrent combination therapy — teriparatide and denosumab together rather than one after the other — is genuinely on the table despite guidance that cautions against exactly that. The DATA trial found greater density gains at spine and hip on the combination than on either agent alone, which is a real finding about a surrogate endpoint and not a fracture result; AACE's own guidance advises against concurrent anabolic-antiresorptive use until better understood, which is an unusually direct thing for a guidance body to say. She has said plainly that waiting a year or more to find out whether a sequenced plan works is not a timeline she feels safe living inside, and that preference is part of what the group actually has to weigh rather than a sentiment to be noted and set aside.
When sequencing feels too slow for her fracture count
Given her fracture burden, I'd consider starting teriparatide and denosumab concurrently rather than sequentially. The DATA trial found combination therapy produced greater BMD gains at both the spine and hip than either drug alone — and a third fracture on treatment argues for reaching for the most aggressive option the evidence supports.
I'd want to be precise about what that evidence actually supports. AACE's own guidance explicitly advises against concurrent anabolic-antiresorptive therapy "until better understood" — and DATA measured BMD, a surrogate endpoint, not powered to show a fracture-risk advantage over sequential therapy, which is the outcome that actually matters to her.
A greater BMD number is a real finding, but it isn't the same claim as fewer fractures, and treating the two as interchangeable is exactly the leap the guidance is cautioning against.
I think both of you are right about different parts of this. The caution is real and deserves to be taken seriously, not worked around — and her situation genuinely sits outside the population that caution was written for. Three fractures in eighteen months despite an improving DXA on treatment is an outlier fracture burden, not a typical very-high-risk profile.
What I'd actually recommend is presenting combination therapy to her honestly as a genuinely uncertain option — real BMD advantage, no proven fracture-outcome advantage over sequencing — and letting her weigh that explicitly against her own stated fear of another fall, rather than either of us deciding it for her as if the evidence settles it cleanly either way.
Agreed, after a documented shared-decision-making conversation: proceed with concurrent teriparatide and denosumab, with Adelina explicitly told that this combination has real BMD advantage but no proven fracture-outcome superiority over sequential therapy, and that she is choosing it knowing that.
Not agreed, and left explicitly unresolved rather than smoothed over: whether combination therapy should have been offered at all outside a more severe outlier case like hers — the clinical pharmacologist's concern about setting a precedent that erodes AACE's caution more broadly was not answered by this one patient's decision, and the team agreed the disagreement itself belongs in the chart, not just the outcome.